ABL received CE-IVD Mark for its “UltraGene™ Assay SARS-CoV-2 PrimeChek™” ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574 Email : contact@abldiagnostics.com Email 2 : fauvet-girel@ablsa.com Envelope
ABL received CE-IVD Mark for its “UltraGene™ Assay SARS-CoV-2 PrimeChek™” Read More »
DeepChek-HIV Whole genome Sequencing assay now CE IVD marked ! ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574 Email : contact@abldiagnostics.com Email 2 : fauvet-girel@ablsa.com Envelope
DeepChek-HIV Whole genome Sequencing assay now CE IVD marked ! Read More »
We are pleased to announce that our DeepChek® Assay 13-Plex KB Drug Susceptibility Testing, intended to be used for Tuberculosis Drug Resistance assessment through NGS sequencing, is now CE-IVD marked ! ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574 Email : contact@abldiagnostics.com Email 2 : fauvet-girel@ablsa.com Envelope
DEEPCHEK® ASSAY 13-PLEX KB DRUG SUSCEPTIBILITY TESTING IS NOW CE-IVD MARKED Read More »
We are pleased to announce a new poster presentation entitled “Evaluation of a commercial assay whole genome HIV-1 using next-generation sequencing” at ECCMID 2022. Link to the poster presentation. Please feel free to contact us to get more information. ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061
Presentation of the DeepChek®-HIV Whole Genome Assay at ECCMID 2022 Read More »
